Trial Profile
Retrospective observational study in patients with renal cell carcinoma treated by everolimus, mTOR inhibitor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 17 Jun 2011 Planned end date changed from 1 Apr 2012 to 1 Sep 2012 as reported by University Hospital Medical Information Network - Japan.
- 20 Dec 2010 New trial record